Marek Horynski
Overview
Explore the profile of Marek Horynski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
57
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanauer S, Sands B, Schreiber S, Danese S, Klopocka M, Kierkus J, et al.
Gastroenterology
. 2024 May;
167(5):919-933.
PMID: 38788861
Background & Aims: CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of...
2.
Jairath V, Zou G, Wang Z, Adsul S, Colombel J, DHaens G, et al.
BMJ Open Gastroenterol
. 2024 Feb;
11(1).
PMID: 38336367
Introduction: Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower...
3.
Dignass A, Stremmel W, Horynski M, Poyda O, Armerding P, Fellermann K, et al.
Clin Gastroenterol Hepatol
. 2023 Oct;
22(4):810-820.e7.
PMID: 37806372
Background & Aims: The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of remission in patients with...
4.
Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, et al.
Gastroenterology
. 2021 Mar;
160(7):2340-2353.
PMID: 33676969
Background & Aims: This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) vs intravenous CT-P13 (CT-P13 IV)...